PD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024

Programmed cell death-1 (PD-1) inhibitors and programmed cell death ligand 1 (PD-L1) inhibitors are considered effective alternatives for the primary treatment of recurrent metastatic cancers. However, they can induce various adverse events affecting multiple organ systems, potentially diminishing p...

Full description

Saved in:
Bibliographic Details
Main Authors: Qingya Song, Zongliang Yu, Wenping Lu, Zhili Zhuo, Lei Chang, Heting Mei, Yongjia Cui, Dongni Zhang
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2024.2424611
Tags: Add Tag
No Tags, Be the first to tag this record!